Lucanthone

DRUG2 trials

Sponsors

Spectrum Pharmaceuticals, Inc, Wake Forest University Health Sciences

Conditions

Brain MetastasesGlioblastoma MultiformeNon-small Cell Lung Cancer

Phase 2

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

TerminatedNCT01587144

Spectrum Pharmaceuticals, IncGlioblastoma Multiforme

Start: 2012-06-19End: 2013-04-15Updated: 2021-10-19

Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

WithdrawnNCT02014545

Wake Forest University Health SciencesBrain Metastases, Non-small Cell Lung Cancer

Start: 2016-01-31End: 2017-11-29Updated: 2018-07-05